Based on the positive association between 4-1BB signaling and the TILs biogenesis, 4-1BB agonist in combination with adoptive cell therapy and PD-1 blockade can further augment cancer elimination based on immunotherapy potency (Menk et al., 2018). This evidence concerns the gene PDCD1 and cancer.